Last reviewed · How we verify
Bisacodyl 5 milligram
Bisacodyl stimulates colonic muscle contractions and increases intestinal fluid secretion to promote bowel evacuation.
Bisacodyl stimulates colonic muscle contractions and increases intestinal fluid secretion to promote bowel evacuation. Used for Constipation, Bowel evacuation prior to diagnostic procedures.
At a glance
| Generic name | Bisacodyl 5 milligram |
|---|---|
| Also known as | dulcolax |
| Sponsor | University of Nottingham |
| Drug class | Contact laxative |
| Target | Colonic smooth muscle and intestinal epithelium |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Bisacodyl is a diphenylmethane laxative that acts as a contact laxative. It is converted by colonic bacteria to its active metabolite, which directly stimulates the smooth muscle of the colon and inhibits water and electrolyte reabsorption in the intestine, thereby increasing stool bulk and promoting defecation.
Approved indications
- Constipation
- Bowel evacuation prior to diagnostic procedures
Common side effects
- Abdominal cramping
- Diarrhea
- Nausea
- Electrolyte imbalance
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisacodyl 5 milligram CI brief — competitive landscape report
- Bisacodyl 5 milligram updates RSS · CI watch RSS
- University of Nottingham portfolio CI